bioRxivEvolutionary Biology
Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs
K. Schmidlin, S. Apodaca, D. Newell, A. Sastokas, G. Kinsler, K. Geiler-Samerotte
Abstract
There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, specifically, whether the mutants that provide resistance to a given drug all suffer similar tradeoffs. This question is difficult because the drug-resistant mutants observed in the clinic, and even those evolved in controlled laboratory settings, are often biased towards those that provide large fitness benefits. Thus, the mutations (and mechanisms) that provide drug resistance may be more diverse than current data suggests. Here, we perform evolution experiments utilizing lineage-tracking to capture a fuller spectrum of mutations that give yeast cells a fitness advantage in fluconazole, a common antifungal drug. We then quantify fitness tradeoffs for each of 774 evolved mutants across 12 environments, finding these mutants group into 6 classes with characteristically different tradeoffs. Their unique tradeoffs may imply that each group of mutants affects fitness through different underlying mechanisms. Some of the groupings we find are surprising. For example, we find some mutants that resist single drugs do not resist their combination, while others do. And some mutants to the same gene have different tradeoffs than others. These findings, on one hand, demonstrate the difficulty in relying on consistent or intuitive tradeoffs when designing multidrug treatments. On the other hand, by demonstrating that hundreds of adaptive mutations can be reduced to a few groups with characteristic tradeoffs, our findings may yet empower multidrug strategies that leverage tradeoffs to combat resistance. More generally speaking, by grouping mutants that likely affect fitness through similar underlying mechanisms, our work guides efforts to map the phenotypic effects of mutation.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cross-feeding affects the target of resistance evolution to an antifungal drug
Romain Durand, Jordan Jalbert-Ross, … Christian R. Landry·PLoS GeneticsPeer-reviewed·Oct 19, 2023
- Adaptive responses to antifungal selection depend on dose and drug combination in experimentally evolved yeast
Megan Sandoval-Powers, Giovanni Alberto Crestani, … Molly K. Burke·bioRxiv·Oct 29, 2026
- Most azole antifungal resistance mutations in the drug target provide cross-resistance and carry no intrinsic fitness cost
C. Bedard, I. Gagnon-Arsenault, … C. R. Landry·bioRxiv·Dec 13, 2023
- Candida albicans genetic background influences mean and heterogeneity of drug responses and genome stability during evolution to fluconazole
A. C. Gerstein, J. Berman·bioRxiv·Feb 27, 2020
- Epistasis-mediated compensatory evolution in a fitness landscape with adaptational tradeoffs
Suman G. Das, Muhittin Mungan, Joachim Krug·Proceedings of the National Academy of SciencesPeer-reviewed·Apr 11, 2025
- The influence of drug dosing regimen on extinction and adaptation during experimental evolution in Candida albicans
Parul Sethi, Erica Pouteau, … Aleeza C. Gerstein·bioRxiv·Oct 30, 2026